The 139 references without contexts in paper Article Editorial , Статья Редакционная (2017) “Легочная гипертензия. Диагностика и лечение. Европейские клинические рекомендации (2015) (часть 2-я) // Pulmonary hypertension. Diagnosis and therapy. European guidelines, 2015 (Part 2)” / spz:neicon:pulmonology:y:2017:i:4:p:447-471

1
Hoeper M.M., Bogaard H.J., Condliffe R. et al. Definitions and diagnosis of pulmonary hypertension. J. Am. Coll. Cardiol.2013; 62 (Suppl.): D42–D50. DOI: 10.1016/j. jacc.2013.10.032.
(check this in PDF content)
2
Kovacs G., Berghold A., Scheidl S. et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: A systematic review.Eur. Respir. J. 2009; 34 (4): 888–894. DOI: 10.1183/09031936.00145608.
(check this in PDF content)
3
Herve P., Lau E., Sitbon O. et al. Criteria for diagnosis of exercise pulmonary hypertension. Eur. Respir. J.2015;
(check this in PDF content)
4
3): 728–737. DOI: 10.1183/09031936.00021915. 4. Vachiery J.L., Adir Y., Barbera J.A. et al. Pulmonary hypertension due to left heart disease. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D100–D108. DOI: 10.1016/j.jacc. 2013.10.033.
(check this in PDF content)
5
Simonneau G., GalièN., Rubin L.J. et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2004; 43 (Suppl. 1): S5–S12.
(check this in PDF content)
6
Simonneau G., Gatzoulis M.A., Adatia I. et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D34–D41. DOI: 10. 1016/j.jacc.2013.10.029.
(check this in PDF content)
7
Dhillon R. The management of neonatal pulmonary hypertension.Arch. Dis. Child Fetal. Neonatal. Ed.2012; 97 (3): F223–F228. DOI: 10.1136/adc.2009.180091.
(check this in PDF content)
8
Porta N.F., Steinhorn R.H. Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents.Clin. Perinatol.2012; 39 (1): 149–164. DOI: 10.1016/j.clp.2011.12.006.
(check this in PDF content)
9
Ivy D.D., Abman S.H., Barst R.J. et al. Pediatric pulmonary hypertension. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D117–D126. DOI: 10.1016/j.jacc.2013.10.028.
(check this in PDF content)
10
Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry.Am. J. Respir. Crit. Care Med. 2006; 173 (9): 1023–1030. DOI: 10.1164/rccm.200510-1668OC.
(check this in PDF content)
11
Peacock A.J., Murphy N.F., McMurray J.J.V. et al. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 2007; 30 (1): 104–109. DOI: 10.1183/0903 1936.00092306.
(check this in PDF content)
12
McGoon M.D., Benza R.L., Escribano-Subias P. et al. Pulmonary arterial hypertension: epidemiology and registries.J. Am. Coll. Cardiol.2013; 62 (25, Suppl.): D51–D59.
(check this in PDF content)
13
Simonneau G., Robbins I., Beghetti M., et al. Updated clinical classification of pulmonary hypertension.J. Am. Coll. Cardiol.2009; 54 (Suppl.): S43–S54.
(check this in PDF content)
14
Montani D., Bergot E., Günther S. et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012; 125 (17): 2128–2137. DOI: 10.1161/ CIRCULATIONAHA.111.079921.
(check this in PDF content)
15
Savale L., Chaumais M.C., Cottin V. et al. Pulmonary hypertension associated with benfluorex exposure. Eur. Respir. J.2012; 40 (5): 1164–1172. DOI: 10.1183/0903 1936.00188611.
(check this in PDF content)
16
Savale L., Sattler C., Gunther S. et al. Pulmonary arterial hypertension in patients treated with interferon. Eur. Respir. J.2014; 44 (6): 1627–1634. DOI: 10.1183/0903 1936.00057914.
(check this in PDF content)
17
Badesch B.D., Champion H.C., Gomez-Sanchez M.A. et al. Diagnosis and assessment of pulmonary arterial hypertension.J. Am. Coll. Cardiol.2009; 54 (Suppl.): S55–S56.
(check this in PDF content)
18
Oudiz R.J. Pulmonary hypertension associated with leftsided heart disease.Clin. Chest Med.2007; 28 (1): 233– 241. DOI: 10.1016/j.ccm.2006.12.001.
(check this in PDF content)
19
Vahanian A., Alfieri O., Andreotti F. et al. Guidelines on the management of valvular heart disease (version 2012). Eur. Heart J. 2012; 33 (19): 2451–2496. DOI: 10.1093/ eurheartj/ehs109.
(check this in PDF content)
20
Seeger W., Adir Y., BarberàJ.A. et al. Pulmonary hypertension in chronic lung diseases. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D109–D116.
(check this in PDF content)
21
Hurdman J., Condliffe R., Elliot C.A. et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur. Respir. J.2013; 41 (6): 1292–1301. DOI: 10.1183/ 09031936.00079512.
(check this in PDF content)
22
Cottin V., Nunes H., Brillet P.Y. et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J.2005; 26 (4): 586–593. DOI: 10. 1183/09031936.05.00021005.
(check this in PDF content)
23
Escribano-Subias P., Blanco I., Lopez-Meseguer M. et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry.Eur. Respir. J.2012; 40 (3): 596–603. DOI: 10.1183/09031936.00101211.
(check this in PDF content)
24
Pengo V., Lensing A.W., Prins M.H. et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med. 2004; 350 (22): 2257–2264. DOI: 10.1056/NEJMoa032274.
(check this in PDF content)
25
Pepke-Zaba J., Delcroix M., Lang I. et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011; 124 (18): 1973–1981. DOI: 10.1161/CIRCULATIONAHA.110.015008.
(check this in PDF content)
27
Ma L., Roman-Campos D., Austin E.D. et al. A novel channelopathy in pulmonary arterial hypertension. N. Engl. J. Med.2013; 369 (4): 351–361. DOI: 10.1056/ NEJMoa1211097.
(check this in PDF content)
28
Eyries M., Montani D., Girerd B. et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat. Genet. 2014; 46 (1): 65–69. DOI: 10.1038/ng.2844.
(check this in PDF content)
29
Eddahibi S., Chaouat A., Morrell N. et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation. 2003; 108 (15): 1839–1844. DOI: 10.1161/ 01.CIR.0000091409.53101.E8.
(check this in PDF content)
30
Bonderman D., Wexberg P., Martischnig A.M. et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur. Respir. J.2011; 37 (5): 1096–1103. DOI: 10.1183/09031936.00089610.
(check this in PDF content)
31
Rich J.D., Thenappan T., Freed B. et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int. J. Cardiol.2013; 167 (3): 669–676. DOI: 10.1016/j.ijcard. 2012.03.071.
(check this in PDF content)
32
Sun P.Y., Jiang X., Gomberg-Maitland M. et al. Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pulmonary arterial hypertension. Chest. 2012; 141: 374–380.
(check this in PDF content)
33
Olsson K.M., Nickel N.P., Tongers J. et al. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int. J. Cardiol.2013; 167 (5): 2300–2305. DOI: 10.1016/ j.ijcard.2012.06.024.
(check this in PDF content)
35
Milne E.N. Forgotten gold in diagnosing pulmonary hypertension: the plain chest radiograph. Radiographics. 2012; 32 (4): 1085–1087. DOI: 10.1148/rg.324125021.
(check this in PDF content)
36
Trip P., Nossent E.J., de Man F.S. et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur. Respir. J.2013; 42 (6): 1575–1585. DOI: 10.1183/ 09031936.00184412.
(check this in PDF content)
37
Sun X.G., Hansen J.E., Oudiz R.J. et al. Pulmonary function in primary pulmonary hypertension.J. Am. Coll. Cardiol. 2003; 41 (6): 1028–1035.
(check this in PDF content)
38
Hoeper M.M., Pletz M.W., Golpon H. et al. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2007; 29 (5): 944–950. DOI: 10.1183/09031936.00134506.
(check this in PDF content)
39
Pellegrino R., Viegi G., Brusasco V. et al. Interpretative strategies for lung function tests. Eur. Respir. J.2005; 26 (5): 948–968. DOI: 10.1183/09031936.05.00035205.
(check this in PDF content)
40
Holverda S., Bogaard H.J., Groepenhoff H. et al. Cardiopulmonary exercise test characteristics in patients with chronic obstructive pulmonary disease and associated pulmonary hypertension. Respiration. 2008; 76 (2): 160–167. DOI: 10.1159/000110207.
(check this in PDF content)
41
Jilwan F.N., Escourrou P., Garcia G. et al. High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. Chest. 2013; 143 (1): 47–55. DOI: 10.1378/chest.11-3124.
(check this in PDF content)
42
Rafanan A.L., Golish J.A., Dinner D.S. et al. Nocturnal hypoxemia is common in primary pulmonary hypertension. Chest. 2001; 120 (3): 894–899.
(check this in PDF content)
43
Rudski L.G., Lai W.W., Afilalo J. et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.J. Am. Soc. Echocardiogr.2010; 23 (7): 685–713. DOI: 10.1016/j.echo.2010.05.010.
(check this in PDF content)
44
Lang R.M., Badano L.P., Mor-Avi V. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 2015; 16 (3): 233–270. DOI: 10.1093/ehjci/ jev014.
(check this in PDF content)
45
Foale R., Nihoyannopoulos P., McKenna W. et al. Echocardiographic measurement of the normal adult right ventricle. Br. Heart J.1986; 56 (1): 33–44.
(check this in PDF content)
46
Hachulla E., Gressin V., Guillevin L. et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum.2005; 52 (12): 3792–3800. DOI: 10.1002/ art.21433.
(check this in PDF content)
47
Tunariu N., Gibbs S.J.R., Win Z. et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J. Nucl. Med.2007; 48 (5): 680–684. DOI: 10.2967/ jnumed.106.039438.
(check this in PDF content)
48
Meng J.J., Zhang L.J., Wang Q. et al. A comparison of ventilation/perfusion single photon emission CT and CT pulmonary angiography for diagnosis of pulmonary embolism. Zhonghua Jie He He Hu Xi Za Zhi.2013; 36 (3): 177–181. Легочная гипертензия. Диагностика и лечение. Европейские клинические рекомендации (2015) (часть 2-я) 464
(check this in PDF content)
49
Rajaram S., Swift A.J., Telfer A. et al. 3D contrastenhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE Registry. Thorax. 2013; 68 (7): 677–678. DOI: 10.1136/thoraxjnl-2012-203020.
(check this in PDF content)
50
Rajaram S., Swift A.J., Condliffe R. et al. CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE Registry. Thorax. 2015; 70 (4): 382–387. DOI: 10.1136/thoraxjnl-2014-206088.
(check this in PDF content)
51
Shen Y., Wan C., Tian P. et al. CT-base pulmonary artery measurement in the detection of pulmonary hypertension: a meta-analysis and systematic review. Medicine(Baltimore). 2014; 93 (27): e256. DOI: 10.1097/MD.000000 0000000256.
(check this in PDF content)
52
Tan R.T., Kuzo R., Goodman L.R. et al. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Chest. 1998; 113 (5): 1250–1256.
(check this in PDF content)
53
Resten A., Maitre S., Humbert M. et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. Am. J. Roentgenol. 2004; 183 (1): 65–70. DOI: 10. 2214/ajr.183.1.1830065.
(check this in PDF content)
54
Dartevelle P., Fadel E., Mussot S. et al. Chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 2004; 23 (4): 637–648.
(check this in PDF content)
55
Reichelt A., Hoeper M.M., Galanski M. et al. Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography. Eur. J. Radiol.2008; 71 (1): 49–54. DOI: 10.1016/ j.ejrad.2008.03.016.
(check this in PDF content)
56
Fedullo P.F., Auger W.R., Kerr K.M. et al. Chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 2001; 345 (20): 1465–1472. DOI: 10.1056/NEJMra 010902.
(check this in PDF content)
57
Fukui S., Ogo T., Morita Y. et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur. Respir. J. 2014; 43 (5): 1394–1402. DOI: 10.1183/0903 1936.00012914.
(check this in PDF content)
58
Castaner E., Alguersuari A., Andreu M. et al. Imaging findings in pulmonary vasculitis. Semin. Ultrasound. CT MR. 2012; 33 (6): 567–579. DOI: 10.1053/j.sult.2012.05.001.
(check this in PDF content)
59
Nawaz A., Litt H.I., Stavropoulos S.W. et al. Digital subtraction pulmonary arteriography versus multidetector CT in the detection of pulmonary arteriovenous malformations.J. Vasc. Interv. Radiol. 2008; 19 (11): 1582–1588. DOI: 10.1016/j.jvir.2008.07.011.
(check this in PDF content)
60
Peacock A.J., Vonk Noordegraaf A. Cardiac magnetic resonance imaging in pulmonary arterial hypertension.Eur. Respir. Rev.2013; 22 (130): 526–534. DOI: 10.1183/0905 9180.00006313.
(check this in PDF content)
61
Swift A.J., Rajaram S., Condliffe R. et al. Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry.J. Cardiovasc. Magn. Reson. 2012; 14: 40–50. DOI: 10.1186/1532-429X-14-40.
(check this in PDF content)
62
Swift A.J., Rajaram S., Hurdman J. et al. Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry. JACC Cardiovasc. Imaging.2013; 6 (10): 1036–1047. DOI: 10.1016/j.jcmg.2013.01.013.
(check this in PDF content)
63
Ley S., Kauczor H.U., Heussel C.P. et al. Value of contrast-enhanced MR angiography and helical CT angiography in chronic thromboembolic pulmonary hypertension. Eur. Radiol.2003; 13 (10): 2365–2371. DOI: 10.1007/ s00330-003-1878-8.
(check this in PDF content)
64
Wolferen S.A., Marcus J.T., Boonstra A. et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur. Heart J.2007; 28 (10): 1250–1257. DOI: 10.1093/ eurheartj/ehl477.
(check this in PDF content)
65
Peacock A.J., Crawley S., McLure L. et al. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension–targeted therapy: the EURO-MR Study. Circ. Cardiovasc. Imaging.2014; 7 (1): 107–114. DOI: 10. 1161/CIRCIMAGING.113.000629.
(check this in PDF content)
66
Veerdonk M.C., Kind T., Marcus J.T. et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.J. Am. Coll. Cardiol.2011; 58 (24): 2511–2519. DOI: 10.1016/ j.jacc.2011.06.068.
(check this in PDF content)
67
Albrecht T., Blomley M.J., Cosgrove D.O. et al. Noninvasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet. 1999; 353 (9164): 1579–1583. DOI: 10.1016/S0140-6736(98)06373-9.
(check this in PDF content)
68
Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. Swiss. Med. Wkly.2003; 133 (11-12): 163–169. DOI: 2003/11/smw-10016.
(check this in PDF content)
69
Hoeper M.M., Lee S.H., Voswinckel R. et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J. Am. Coll. Cardiol. 2006; 48 (12): 2546–2552. DOI: 10. 1016/j.jacc.2006.07.061.
(check this in PDF content)
70
Kovacs G., Avian A., Pienn M. et al. Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. Am. J. Respir. Crit. Care Med.2014; 190: 252–257.
(check this in PDF content)
71
Hoeper M.M., Maier R., Tongers J. et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am. J. Respir. Crit. Care Med.1999; 160 (2): 535–541. DOI: 10. 1164/ajrccm.160.2.9811062.
(check this in PDF content)
72
Frost A.E., Farber H.W., Barst R.J. et al. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. Chest. 2013; 143 (1): 185–195. DOI: 10.1378/chest.11-1387.
(check this in PDF content)
73
Abraham W.T., Adamson P.B., Bourge R.C. et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011; 377 (9766): 658–666. DOI: 10.1016/S0140-6736(11) 60101-3.
(check this in PDF content)
74
Prasad A., Hastings J.L., Shibata S. et al. Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction.Circ. Heart Fail. 2010; 3 (5): 617–626. DOI: 10. 1161/CIRCHEARTFAILURE.109.867044.
(check this in PDF content)
75
Fujimoto N., Borlaug B.A., Lewis G.D. et al. Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation. 2013; 127 (1): 55–62. DOI: 10.1161/CIRCULATIONAHA.112.111302.
(check this in PDF content)
76
Fox B.D., Shimony A., Langleben D. et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur. Respir. J.2013; 42 (4): 1083–1091. DOI: 10.1183/09031936.00091212.
(check this in PDF content)
77
Robbins I.M., Hemnes A.R., Pugh M.E. et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ. Heart Fail. 2014; 7 (1): 116–122. DOI: 10.1161/CIRCHEARTFAILURE.113.000468.
(check this in PDF content)
78
Borlaug B.A., Nishimura R.A., Sorajja P. et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ. Heart Fail. 2010; 3 (5): 588–595. DOI: 10.1161/CIRCHEARTFAILURE. 109.930701.
(check this in PDF content)
79
Hager W.D., Collins I., Tate J.P. et al. Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients.Clin. Respir. J. 2013; 7 (3): 227–236. DOI: 10. 1111/j.1752-699X.2012.00310.x.
(check this in PDF content)
80
Halpern S.D., Taichman D.B. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest. 2009; 136 (1): 37–43. DOI: 10. 1378/chest.08-2784.
(check this in PDF content)
81
Naeije R., Vachiery J.L., Yerly P. et al. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur. Respir. J.2013; 41 (1): 217–223. DOI: 10.1183/09031936.00074312.
(check this in PDF content)
82
Provencher S., Herve P., Sitbon O. et al. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. Eur. Respir. J.2008; 32 (2): 393–398. DOI: 10.1183/09031936.00009008.
(check this in PDF content)
83
Tedford R.J., Beaty C.A., Mathai S.C. et al. Prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. J. Heart Lung Transplant.2014; 33: 289–297. DOI: 10.1056/NEJM199207093270203.
(check this in PDF content)
86
Barst R., McGoon M., Torbicki A. et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2004; 43 (Suppl. 1): S40–S47.
(check this in PDF content)
87
Morgan J.M., McCormack D.G., Griffiths M.J. et al. Adenosine as a vasodilator in primary pulmonary hypertension [see comments]. Circulation. 1991; 84 (83): 1145–1149.
(check this in PDF content)
88
Nootens M., Schrader B., Kaufmann E. et al. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest. 1995; 107 (1): 54–57.
(check this in PDF content)
89
Hoeper M.M., Olschewski H., Ghofrani H.A. et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension.J. Am. Coll. Cardiol.2000; 35 (1): 176–182.
(check this in PDF content)
90
Opitz C.F., Wensel R., Bettmann M. et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur. Heart J.2003; 24: 356–365.
(check this in PDF content)
91
Kim N.H., Delcroix M., Jenkins D.P. et al. Chronic thromboembolic pulmonary hypertension. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D92–D99. DOI: 10.1016/ j.jacc.2013.10.024.
(check this in PDF content)
92
Montani D., Price L.C., Dorfmuller P. et al. Pulmonary veno-occlusive disease.Eur. Respir. J.2009; 33 (1): 189– 200. DOI: 10.1183/09031936.00090608.
(check this in PDF content)
93
He J., Fang W., Lv B. et al. Diagnosis of chronic thromboembolic pulmonary hypertension: comparison of ventilation/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography. Nucl. Med. Commun. 2012; 33 (5): 459–463. DOI: 10.1097/MNM.0b013e32835085d9.
(check this in PDF content)
94
Cottin V., Le Pavec J., Prevot G. et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome.Eur. Respir. J.2010; 35 (1): 105–111. DOI: 10.1183/09031936.00038709.
(check this in PDF content)
95
Taichman D.B., McGoon M.D., Harhay M.O. et al. Wide variation in clinicians’ assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin. Proc.2009; 84 (7): 586–592. DOI: 10.1016/S0025-6196 (11)60747-7.
(check this in PDF content)
98
Barst R.J., Chung L., Zamanian R.T. et al. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest. 2013; 144 (1): 160–168. DOI: 10.1378/chest.12-2417.
(check this in PDF content)
99
Benza R.L., Miller D.P., Gomberg-Maitland M. et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and LongTerm Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122 (2): 164–172. DOI: 10.1161/CIRCULATIONAHA.109.898122.
(check this in PDF content)
100
McLaughlin V.V., Sitbon O., Badesch D.B. et al. Survival with first-line bosentan in patients with primary pulmonary hypertension.Eur. Respir. J.2005; 25 (2): 244–249. DOI: 10.1183/09031936.05.00054804.
(check this in PDF content)
101
Sachdev A., Villarraga H.R., Frantz R.P. et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. Chest. 2011; 139 (6): 1299–1309. DOI: 10.1378/chest.10-2015.
(check this in PDF content)
102
Raymond R.J., Hinderliter A.L., Willis P.W. et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension.J. Am. Coll. Cardiol. 2002; 39 (7): 1214–1219.
(check this in PDF content)
103
Bustamante-Labarta M., Perrone S., De La Fuente R.L. et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. J. Am. Soc. Echocardiogr.2002; 15 (10, Pt 2): 1160–1164.
(check this in PDF content)
104
Forfia P.R., Fisher M.R., Mathai S.C. et al. Tricuspid annular displacement predicts survival in pulmonary hypertension.Am. J. Respir. Crit. Care Med. 2006; 174 (9): 1034–1041. DOI: 10.1164/rccm.200604-547OC.
(check this in PDF content)
105
Thenappan T., Shah S.J., Rich S. et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur. Respir. J. 2010; 35 (5): 1079–1087. DOI: 10.1183/09031936.00072709.
(check this in PDF content)
106
Wensel R., Opitz C.F., Anker S.D. et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circula' tion. 2002; 106 (3): 319–324.
(check this in PDF content)
108
Fine N.M., Chen L., Bastiansen P.M. et al. Outcome prediction by quantitative right ventricular function assessЛегочная гипертензия. Диагностика и лечение. Европейские клинические рекомендации (2015) (часть 2-я) 466 ment in 575 subjects evaluated for pulmonary hypertension.Circ. Cardiovasc. Imaging.2013; 6 (5): 711–721. DOI: 10.1161/CIRCIMAGING.113.000640.
(check this in PDF content)
109
Shimada Y.J., Shiota M., Siegel R.J. et al. Accuracy of right ventricular volumes and function determined by three-dimensional echocardiography in comparison with magnetic resonance imaging: a meta-analysis study. J. Am. Soc. Echocardiogr.2010; 23 (9): 943–953. DOI: 10.1016/ j.echo.2010.06.029.
(check this in PDF content)
110
Smith B.C., Dobson G., Dawson D. et al. Three-dimensional speckle tracking of the right ventricle: toward optimal quantification of right ventricular dysfunction in pulmonary hypertension. J. Am. Coll. Cardiol.2014; 64 (1): 41–51. DOI: 10.1016/j.jacc.2014.01.084.
(check this in PDF content)
111
Grunig E., Tiede H., Enyimayew E.O. et al. Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension. Circulation. 2013; 128 (18): 2005–2015. DOI: 10.1161/ CIRCULATIONAHA.113.001573.
(check this in PDF content)
112
Swift A.J., Rajaram S., Marshall H. et al. Black blood MRI has diagnostic and prognostic value in the assessment of patients with pulmonary hypertension.Eur. Radiol. 2012; 22 (3): 695–702. DOI: 10.1007/s00330-011-2306-0.
(check this in PDF content)
113
Swift A.J., Rajaram S., Campbell M.J. et al. Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ. Cardiovasc. Imaging. 2014; 7 (1): 100–106. DOI: 10.1161/CIRCIMAGING. 113.000338.
(check this in PDF content)
114
Sitbon O., McLaughlin V.V., Badesch D.B. et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005; 60 (12): 1025–1030. DOI: 10.1136/thx.2005.040618.
(check this in PDF content)
115
Rich J.D., Archer S.L., Rich S. Noninvasive cardiac output measurements in patients with pulmonary hypertension. Eur. Respir. J.2013; 42 (1): 125–133. DOI: 10.1183/ 09031936.00102212.
(check this in PDF content)
116
Savarese G., Paolillo S., Costanzo P. et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J. Am. Coll. Cardiol.2012; 60 (13): 1192–1201. DOI: 10.1016/j.jacc.2012.01.083.
(check this in PDF content)
117
Gabler N.B., French B., Strom B.L. et al. Validation of 6minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation. 2012; 126 (3): 349–356. DOI: 10.1161/CIRCULATIONAHA.112. 105890.
(check this in PDF content)
118
Fritz J.S., Blair C., Oudiz R.J. et al. Baseline and followup 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest. 2013; 143 (2): 315–323. DOI: 10.1378/chest.120270.
(check this in PDF content)
119
Paciocco G., Martinez F., Bossone E. et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur. Respir. J. 2001; 17 (4): 647–652.
(check this in PDF content)
120
Provencher S., Chemla D., Herve P. et al. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur. Respir. J. 2006; 27 (1): 114– 120. DOI: 10.1183/09031936.06.00042705.
(check this in PDF content)
121
Sun X.G., Hansen J.E., Oudiz R.J. et al. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation. 2001; 104 (4): 429–435.
(check this in PDF content)
122
Wensel R., Francis D.P., Meyer F.J. et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int. J. Cardiol. 2013; 167 (4): 1193–1198. DOI: 10. 1016/j.ijcard.2012.03.135.
(check this in PDF content)
123
Blumberg F.C., Arzt M., Lange T. et al. Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension. Eur. J. Heart Fail. 2013; 15 (7): 771–775. DOI: 10.1093/eurjhf/hft044.
(check this in PDF content)
124
Diller G.P., Dimopoulos K., Okonko D. et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circula' tion. 2005; 112 (6): 828–835. DOI: 10.1161/CIRCULATIONAHA.104.529800.
(check this in PDF content)
125
Arena R., Lavie C.J., Milani R.V. et al. Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. J. Heart Lung Transplant.2010; 29 (2): 159–173. DOI: 10.1016/j.healun. 2009.09.003.
(check this in PDF content)
126
Pullamsetti S., Kiss L., Ghofrani H.A. et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J. 2005; 19 (9): 1175–1177. DOI: 10.1096/fj.04-3223fje.
(check this in PDF content)
127
Kielstein J.T., Bode-Boger S.M., Hesse G. et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler. Thromb. Vasc. Biol.2005; 25 (7): 1414–1418. DOI: 10.1161/01.ATV.0000168414. 06853.f0.
(check this in PDF content)
128
Kielstein J.T., Impraim B., Simmel S. et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. 2004; 109 (2): 172–177. DOI: 10.1161/01.CIR.00001 05764.22626.B1.
(check this in PDF content)
129
Kawut S.M., Horn E.M., Berekashvili K.K. et al. von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest. 2005; 128 (4): 2355–2362. DOI: 10.1378/chest. 128.4.2355.
(check this in PDF content)
130
Kümpers P., Nickel N., Lukasz A. et al. Circulating angiopoietins in idiopathic pulmonary arterial hypertension.Eur. Heart J.2010; 31 (18): 2291–2300. DOI: 10. 1093/eurheartj/ehq226.
(check this in PDF content)
131
Rubens C., Ewert R., Halank M. et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001; 120 (5): 1562–1569.
(check this in PDF content)
132
Quarck R., Nawrot T., Meyns B. et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J. Am. Coll. Cardiol.2009; 53 (14): 1211– 1218. DOI: 10.1016/j.jacc.2008.12.038.
(check this in PDF content)
133
Balabanian K., Foussat A., Dorfmuller P. et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.2002; 165 (10): 1419–1425. DOI: 10.1164/rccm.2106007.
(check this in PDF content)
134
Dorfmuller P., Zarka V., Durand-Gasselin I. et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2002; 165 (4): 534–539. DOI: 10.1164/ajrccm.165.4.2012112.
(check this in PDF content)
135
Humbert M., Monti G., Brenot F. et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med.1995; 151 (5): 1628–1631. DOI: 10.1164/ajrccm. 151.5.7735624.
(check this in PDF content)
136
Nagaya N., Nishikimi T., Uematsu M. et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000; 102 (8): 865–870.
(check this in PDF content)
137
Leuchte H.H., El Nounou M., Tuerpe J.C. et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest. 2007; 131 (2): 402–409. DOI: 10.1378/chest.06-1758.
(check this in PDF content)
138
Fijalkowska A., Kurzyna M., Torbicki A. et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006; 129 (5): 1313–1321. DOI: 10.1378/chest.129.5. 1313.
(check this in PDF content)
139
Torbicki A., Kurzyna M., Kuca P. et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation. 2003; 108 (7): 844–848. DOI: 10.1161/ 01.CIR.0000084544.54513.E2.
(check this in PDF content)
140
Nickel N., Kempf T., Tapken H. et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2008; 178 (5): 534– 541. DOI: 10.1164/rccm.200802-235OC.
(check this in PDF content)
141
Nagaya N., Uematsu M., Satoh T. et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension.Am. J. Respir. Crit. Care Med. 1999; 160 (2): 487–492. DOI: 10.1164/ajrccm.160. 2.9812078.
(check this in PDF content)
142
Lorenzen J.M., Nickel N., Kramer R. et al. Osteopontin in patients with idiopathic pulmonary hypertension. Chest. 2011; 139 (5): 1010–1017. DOI: 10.1378/chest.10-1146.
(check this in PDF content)
143
Warwick G., Thomas P.S., Yates D.H. Biomarkers in pulmonary hypertension. Eur. Respir. J.2008; 32 (2): 503– 512. DOI: 10.1183/09031936.00160307.
(check this in PDF content)
144
Hoeper M.M., Markevych I., Spiekerkoetter E. et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur. Respir. J. 2005; 26 (5): 858–863. DOI: 10.1183/09031936.05.00075305.
(check this in PDF content)
145
McLaughlin V.V., Gaine S.P., Howard L.S. et al. Treatment goals of pulmonary hypertension.J. Am. Coll. Cardiol.2013; 62 (25, Suppl.): D73–D81.
(check this in PDF content)
210
Vachiery J.L., Huez S., Gillies H. et al. Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. Br. J. Clin. Pharmacol.2011; 71 (2): 289–292. DOI: 10.1111/j. 1365-2125.2010.03831.x.
(check this in PDF content)